Rhythm Pharmaceuticals, Inc.
RYTMNASDAQHealthcare● Active
$85.80
$-0.61(-0.70%)
Market Cap$5.9B
P/E Ratio—
52W High$122.2
52W Low$60.7
Rhythm Pharmaceuticals, Inc. (RYTM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RYTM · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.19B | $0.13B | $0.08B | $0.02B | $0.00B |
| Cost of Revenue | $0.02B | $0.01B | $0.01B | $0.00B | $0.00B |
| Gross Profit | $0.17B | $0.12B | $0.07B | $0.02B | $0.00B |
| Gross Margin %(computed) | 89.73% | 89.73% | 87.99% | 90.98% | 81.01% |
| Operating Expenses | |||||
| R&D Expenses | $0.17B | $0.24B | $0.13B | $0.11B | $0.10B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.36B | $0.38B | $0.25B | $0.20B | $0.17B |
| Operating Income | ($0.19B) | ($0.27B) | ($0.18B) | ($0.18B) | ($0.17B) |
| Operating Margin %(computed) | -101.19% | -204.04% | -238.10% | -757.92% | — |
| Interest Income | $0.02B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.02B | $0.02B | $0.01B | $0.01B | $0.00B |
| Income Before Tax | ($0.20B) | ($0.26B) | ($0.18B) | ($0.18B) | ($0.07B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.20B) | ($0.26B) | ($0.18B) | ($0.18B) | ($0.07B) |
| Net Margin %(computed) | -103.57% | -200.27% | -238.52% | -766.22% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.11 | $-4.34 | $-3.20 | $-3.51 | $-1.37 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.05B | 0.05B |
| EBITDA | ($0.17B) | ($0.24B) | ($0.17B) | ($0.17B) | ($0.07B) |
| EBITDA Margin %(computed) | -91.76% | -182.97% | -217.58% | -737.14% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Rhythm Pharmaceuticals, Inc. data
About Rhythm Pharmaceuticals, Inc. (RYTM) Income Statement
Rhythm Pharmaceuticals, Inc. (RYTM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RYTM reported revenue of $0.19B, gross profit of $0.17B (gross margin 89.73%), and net income of ($0.20B) — a net profit margin of -103.57%.
Frequently asked questions
RYTM · 4 questionsRhythm Pharmaceuticals, Inc. (RYTM) reported revenue of $0.19B for 2025, up 45.8% year-over-year.
RYTM revenueRYTM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08